Funding for this research was provided by:
California Institute for Regenerative Medicine (DR3-06924)
Received: 17 February 2020
Revised: 11 August 2020
Accepted: 5 October 2020
First Online: 23 October 2020
Compliance with ethical standards
: Cirmtuzumab was developed by TJK and licensed from the University of California, San Diego, to Oncternal Therapeutics, Inc., which provided stock/options and funding to the University of California, San Diego, and to TJK.